Sumatriptan
Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
Sumatriptan is the prototypical triptan and the first serotonin 5-HT1B/1D receptor agonist developed specifically for the acute treatment of migraine attacks with or without aura. It is also effective for cluster headache. Available in oral, nasal spray, and subcutaneous injection formulations for flexibility based on attack severity and associated nausea.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
Sumatriptan is the prototypical triptan and the first serotonin 5-HT1B/1D receptor agonist developed specifically for the acute treatment of migraine attacks with or without aura. NutriStack rates the supporting evidence as strong. Common adult dosing is 50-100 mg oral; 6 mg subcutaneous; 5-20 mg intranasal; may repeat after 2 hours if needed, max 200 mg oral/day or 12 mg SC/day (as prescribed by your physician), though a prescriber sets the actual dose. This profile indexes 10 sources.
- Tingling, warmth, and flushing (triptan sensations)
- Chest tightness or pressure (usually non-cardiac)
- Dizziness
- Ischemic heart disease, coronary artery vasospasm (Prinzmetal's angina), or uncontrolled hypertension
- History of stroke or TIA
The bottom line
Evidence rating strong. Most-documented uses: rapid relief of migraine headache, nausea, and photophobia, subcutaneous injection provides relief within 10-15 minutes, effective for cluster headache. 10 sources indexed (1994–2021), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Selectively activates serotonin 5-HT1B receptors on intracranial blood vessels, causing vasoconstriction of dilated meningeal and cerebral arteries. Also activates 5-HT1D receptors on trigeminal nerve terminals, inhibiting release of pro-inflammatory neuropeptides (CGRP, substance P) and blocking pain signal transmission through the trigeminovascular system.6
Dosing & protocol.
Oral bioavailability ~15% due to first-pass metabolism and incomplete absorption; subcutaneous bioavailability 97%. Migraine-related gastroparesis may further delay oral absorption.
Full safety detail.
Side effects
- Tingling, warmth, and flushing (triptan sensations)
- Chest tightness or pressure (usually non-cardiac)
- Dizziness
- Injection site reactions (SC formulation)
- Fatigue and drowsiness
- Medication overuse headache (with frequent use >10 days/month)
- Serotonin syndrome (rare; risk increased with concurrent SSRIs, SNRIs, or TCAs)
Contraindications
- Ischemic heart disease, coronary artery vasospasm (Prinzmetal's angina), or uncontrolled hypertension
- History of stroke or TIA
- Peripheral vascular disease
- Concurrent use with MAO-A inhibitors (within 2 weeks) or ergot-containing medications (within 24 hours)
- Hemiplegic or basilar migraine1,2
- Severe hepatic impairment
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Meta-analyses & systematic reviews
3- 1Beyond its anti-migraine properties, sumatriptan is an anti-inflammatory agent: A systematic reviewPMIDAla M, Ghasemi M, Mohammad Jafari R et al. · Drug development research · 2021
Ala M, Ghasemi M, Mohammad Jafari R et al.. Beyond its anti-migraine properties, sumatriptan is an anti-inflammatory agent: A systematic review. Drug development research. 2021
- 2Intranasal sumatriptan for acute migraine attacks: a systematic review and meta-analysisPMIDMenshawy A, Ahmed H, Ismail A et al. · Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2018
Menshawy A, Ahmed H, Ismail A et al.. Intranasal sumatriptan for acute migraine attacks: a systematic review and meta-analysis. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2018
- 3Safety of sumatriptan in pregnancy: a review of the data so farPMIDLoder E · CNS drugs · 2003
Loder E. Safety of sumatriptan in pregnancy: a review of the data so far. CNS drugs. 2003
Reviews & position papers
2- 4Sumatriptan/Naproxen Sodium: A Review in MigrainePMIDSyed YY · Drugs · 2016
Syed YY. Sumatriptan/Naproxen Sodium: A Review in Migraine. Drugs. 2016
- 5The clinical profile of sumatriptan: safety and tolerabilityPMIDLloyd K · European neurology · 1994
Lloyd K. The clinical profile of sumatriptan: safety and tolerability. European neurology. 1994
Reference material
5- 6Ferrari MD et al. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001;358(9294):1668-1675.Source linkedPMID
- 7Tfelt-Hansen P et al. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000;60(6):1259-1287.Source linkedPMID
- 8Derry CJ et al. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev. 2012;(2):CD008615.Source linkedPMID
- 9Wilcha RJ, Afridi SK, Barbanti P et al.. Sumatriptan-naproxen sodium in migraine: A review. European journal of neurology. 2024Source linkedPMID
- 10Maghbooli M, Golipour F, Moghimi Esfandabadi A et al.. Comparison between the efficacy of ginger and sumatriptan in the ablative treatment of the common migraine. Phytotherapy research : PTR. 2014Source linkedPMID
Common questions.
Quick answers about Sumatriptan, drawn from the data on this page.
What is Sumatriptan?
Sumatriptan is the prototypical triptan and the first serotonin 5-HT1B/1D receptor agonist developed specifically for the acute treatment of migraine attacks with or without aura. It is also effective for cluster headache. Available in oral, nasal spray, and subcutaneous injection formulations for flexibility based on attack severity and associated nausea.
What is Sumatriptan used for?
Commonly cited benefits of Sumatriptan include: Rapid relief of migraine headache, nausea, and photophobia; Subcutaneous injection provides relief within 10-15 minutes; Effective for cluster headache; Multiple delivery routes available. NutriStack rates the overall evidence as strong.
What is a typical dose of Sumatriptan?
A typical adult dose of Sumatriptan is 50-100 mg oral; 6 mg subcutaneous; 5-20 mg intranasal; may repeat after 2 hours if needed, max 200 mg oral/day or 12 mg SC/day (as prescribed by your physician). The commonly recommended form is Oral tablets for mild-moderate attacks; subcutaneous injection (6 mg) for severe attacks or when nausea prevents oral dosing. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Sumatriptan?
Reported side effects include tingling, warmth, and flushing (triptan sensations), chest tightness or pressure (usually non-cardiac), dizziness, injection site reactions (sc formulation), fatigue and drowsiness, medication overuse headache (with frequent use >10 days/month). This is educational information; check with a healthcare professional before use.
How strong is the evidence for Sumatriptan?
NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Sumatriptan in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.